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Post-translational modiﬁcations (PTM) of proteins determine the activity, stability, speciﬁcity, trans-
portability and lifespan of a protein. Some PTM are highly speciﬁc and regulated involving various
enzymatic pathways, but there are other non-enzymatic PTM (nePTM), which occur stochastically,
depend on the ternary structure of proteins and can be damaging. It is often observed that inactive and
abnormal proteins accumulate in old cells and tissues. The nature, site and extent of nePTM give rise to a
population of that speciﬁc protein with alterations in structure and function ranging from being fully
active to totally inactive molecules. Determination of the type and the amount (abundance) of nePTM is
essential for establishing connection between speciﬁc protein structure and speciﬁc biological role. This
article summarizes analytical demands for reliable quantiﬁcation of nePTM, including requirements for
the assay performance, standardization and quality control, and points to the difﬁculties, uncertainties
and un-resolved issues.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
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Common to all biological processes are molecular interactions,
which include binding, followed by a cascade of reactions leading
to speciﬁc physiological events. A cascade may consist of manyunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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ﬁrst event induces an ordered series of happenings that deter-
mines the so-called normal healthy state of a biological system.
However, the biochemical processes that sustain life are prone to
alterations owing to intrinsic and extrinsic factors and these
changes underlie the emergence of ageing and diseases. Although
most physiological macromolecules ﬁt into a general binding-
propagating pathway, this article deals with proteins, their inter-
actions, effects of post-translational structural modiﬁcations, and
the importance of standardization and quality control in the
detection and measurement of molecular forms in physiological
samples. Before analyzing difﬁculties in quantiﬁcation of speciﬁc
protein forms, we recapitulate some structural and binding prop-
erties of proteins, as follows.Folding and binding properties of proteins
All proteins exist as a population of many conformational
states, known as conformers. Multiple conformers are derived
from molecular motions that do not demand signiﬁcant energy
input, resulting in molecular states of similar stability [1]. Motions
are predominantly at the level of side-chains, but the polypeptide
backbone may also exert some ﬂexibility. Although native protein
conformation is dependent primarily on the amino-acid sequence,
the surrounding environment contributes as well. The larger the
molecule, the more conformers are likely to exist. Distribution of
conformers is not even, as some are present in greater proportion
and others in much smaller quantities. This dynamic population
equilibrium shifts in the presence of a binding partner (ligand),
which will “select” the favorable conformer (the one to interact
with), causing redistribution of the conformer set. According to the
concept of a pre-existing population of conformers [2], the ligand
“chooses” the most suitable one from the “library” of offered
molecules. The binding process further stabilizes the complex by
optimizing protein folding and enabling new non-covalent inter-
actions both within the protein and with the ligand. Along the
cascade of interactions, each additional step induces conforma-
tional adjustments leading to multi-molecular complexes that will
trigger speciﬁc physiological events.
Researchers use different words to express their understanding
of molecular ﬂexibility, introducing concepts such as intrinsic
disorder, controlled chaos, conformational breathing or structural
plasticity [3]. Proteins with a greater number of conformers
exhibit more ﬂexible ligand binding capacity, enabling interactions
with a range of ligands [2]. These ligands may have homologous
structure, but even dissimilar ligands may bind to the same site.
The most typical examples are proteases and their substrates,
which possess appropriate short amino-acid sequence regardless
of the rest of the molecule [4]. Other examples are proteins
involved in the innate immune response, where they recognize
certain motives within a range of native molecules [5]. Antibodies
bind epitopes which ﬁt conformationally into Fab pockets,
regardless of the appearance of the remaining molecule [6].
Computer modeling analysis has provided the information that
proteins with a greater degree of conformational change utilize
more interfaces for interactions [7].Post-translational modiﬁcations of proteins
Accurate translation of mRNA, followed by appropriate mod-
iﬁcations of the polypeptide chain, is essential for normal folding,
targeting and speciﬁcity. Misregulation in any of these steps
can have far reaching biological consequences, including effects
on cell growth, division and survival. Many post-translationalmodiﬁcations (PTM) of proteins have been described that deter-
mine their activity, stability, speciﬁcity, transportability and life-
span [8]. There are two distinct types of protein modiﬁcation, one
initiated (programmed) and catalyzed in the presence of speciﬁc
enzymes (enzymatic modiﬁcations), and the other which occurs in
the presence of compounds chemically reactive with proteins (e.g.
reactive oxygen- and nitrogen-species) or is due to physical
modiﬁcation (e.g. irradiation). The second type of modiﬁcation is
known as non-enzymatic. Enzyme catalyzed PTM include phos-
phorylation, acetylation, glycosylation, ribosylation, methylation
and some oxidation reactions such as formation of disulﬁde bonds
and nitrosylation. Non-enzymatic post-translational modiﬁcations
(nePTM) occur stochastically, depend on the ternary structure and
can be physiologically damaging [9]. Such nePTM include oxida-
tion, glycation, deamidation, racemization and isomerization.
Different reactive species are responsible for the formation of a
range of oxidative products, while different amino-acid side chains
can undergo modiﬁcation contributing to an additional variety of
derivatives. Some of these end-products are unstable, present in
very low quantities and decompose quickly. The physiological
response of an organism to nePTM proteins can be repair or
degradation. Lysosomal or proteasomal degradation systems are
primarily involved in the removal of damaged proteins [10], but
cell surface receptors participate as well [11]. Other modiﬁed
proteins acquire stability by further structural adjustments, which
may end with misfolding. A misfolded protein has an increased
chance of self-aggregation into insoluble ﬁbrillar structures, which
accumulate in cells and tissues. Fibrils display common cross-β
sheets, regardless of the original protein structure. A strategy to
reduce ﬁbrillogenesis involves stabilization of the native structure,
for example by binding an appropriate ligand [3]. That event
would favor non-covalent inter-molecular interactions which do
not encourage self-assembly [12]. Formation of amyloid ﬁbrils
underlines neurodegenerative disorders associated with ageing
[13].
Proteins are not equally vulnerable to non-enzymatic mod-
iﬁcations. In general, abundant and long living proteins have the
most easily observed nePTM. Half-lives of soluble proteins are
generally shorter than those of structural proteins, so the effects of
modiﬁcation may be limited and relatively small. If, however,
conditions under which nePTM form last for a long period (i.e.
permanent exposure to modifying agents), the consequences of
even short-living derivatives may be serious. Besides half-life and
concentration, the sequence and conformation of the protein
contribute to its overall susceptibility to modiﬁcation. Oxidation of
ﬁbrinogen, for example, occurs more readily than oxidation of
albumin, immunoglobulins or transferrin [14]. Modiﬁcations of
intracellular proteins induce functional metabolic changes. Pro-
teins in mitochondria are subjected to oxidation more intensively
than those in other compartments [15]. Oxidative changes of
endothelial proteins are also common, underlying the pathogen-
esis of cardiovascular diseases [16]. Speciﬁc examples of modiﬁed
proteins will be given further in the text, where appropriate.Accumulation of abnormal proteins during ageing
It is often observed that inactive and abnormal proteins accu-
mulate in old cells and tissues [17,18]. This increased amount of
debris in the cytoplasm can be inhibitory for cell growth and
normal metabolism, and thus contributes towards failure of
maintenance. One reason for inactivation of an enzyme can be
oxidative modiﬁcation by oxygen free radicals, by mixed-function
oxidation (MFO) systems or by metal catalyzed oxidation (MCO)
systems. Since some amino-acid residues, particularly Pro, Arg, Thr
and Lys, are oxidized to carbonyl derivatives, the carbonyl content
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during ageing [19,20].
An increase in the level of oxidatively modiﬁed proteins has
been reported in old human erythrocytes of higher density and in
cultured human ﬁbroblasts from normal old donors and from
individuals suffering from progeria and Werner’s syndrome
[21,22]. Similarly, there was a twofold increase in the carbonyl
content of brain proteins of retired breeder Mongolian gerbils,
which was reversed by treatment with the spin-trapping com-
pound N-tert-butyl-phenylnitrone [23]. An age-related increase in
the carbonyl content has also been reported in houseﬂies, fruit-
ﬂies, nematodes and mouse organs [17,18]. Declining activity of
6-phosphogluconate dehydrogenase and liver malic enzyme dur-
ing ageing is related to the loss of Lys and His residues by oxida-
tion. Oxidation of a Cys residue in glyceraldehyde-3-phosphate
dehydrogenase may be responsible for its inactivation during
ageing in rat muscles. Similarly, oxidatively-induced disulﬁde
bridges in Cys and Met lead to the formation of sulfenic acid,
sulﬁnic acid and methionine sulfoxide, which can accumulate
during ageing [24]. It has also been reported that the concentra-
tion of oxidation products in human lens proteins and skin col-
lagen increases along with the accumulation of oxidative forms of
alpha-crystallin in patients with age-related cataract [25].
Structural alterations introduced into proteins by oxidation can
lead to aggregation, fragmentation, denaturation and distortion of
secondary and tertiary structure, thereby increasing the proteo-
lytic susceptibility of oxidized proteins. Furthermore, toxic pro-
ducts of carbonyl modiﬁcations can react with other macro-
molecules and affect various metabolic processes. Oxygen, nitro-
gen and other reactive species can moderately change protein
structure (mostly via interactions at side chains) or even cleave the
protein into fragments (mostly via interactions at the backbone)
[26,27].
Glycation is another prevalent covalent modiﬁcation in which
the free amino groups of proteins react with glucose to form keto-
amines, called Amadori products. This is followed by a sequence of
further reactions and rearrangements producing the so-called
advanced glycosylation end products (AGEs) [28]. Most commonly,
it is the long-lived structural proteins, such as lens crystallins,
collagen and basement membrane proteins, which are most sus-
ceptible to glycation. In the case of skin, vimentin has been found
to be the main protein becoming glycated during ageing [29].
Glycated proteins are more prone to form cross-links with other
proteins, leading to structural and functional alterations. Elevated
levels of glycated proteins during ageing have been observed in a
wide variety of systems [28]. For example, there is an increase in
glycated Lys residues in rat sciatic nerve, aorta and skin collagen
during ageing. Glycation of human collagen and osteocalcin is
augmented during ageing. The formation and accumulation of
AGEs are implicated in the physiology and pathology of senes-
cence. It has been observed that pentosidine (cross-linked glycated
Lys and Arg), carboxylmethyl-lysine (CML, glycated and oxidized
proteins) and pyrroline increase with age in normal and diabetic
humans [30]. By using AGE-speciﬁc antibodies, an AGE-modiﬁed
form of human hemoglobin has been identiﬁed, the levels of
which increase during ageing and in patients with diabetes-
induced hyperglycemia [31,32].
There is, however, a serious methodological limitation in
assessing the signiﬁcance of reported changes in the levels of
nePTM proteins during ageing. Since there is an extremely low
probability that any two molecules will be modiﬁed/damaged in
exactly the same way and to the same extent, an increase in
molecular heterogeneity is inevitable [18]. Furthermore, the nat-
ure, site and extent of damage will give rise to a population of a
speciﬁc protein with alterations in structure and function ranging
from being fully active to totally inactive molecules. Of course,among the thousands of types of proteins in a cell, some may be
preferentially damaged in a particular context. For example, it has
been reported that among 1000–2000 proteins inside mitochon-
dria, aconitase is preferentially damaged oxidatively [33]. Some
other proteins known to be prone to oxidation include Hsp70,
protein elongation factors, glutamine synthetase, glutamate syn-
thetase and pyruvate kinase. Similarly, vimentin is the speciﬁc
target of glycation among thousands of other proteins in the skin.
Therefore, accurate identiﬁcation, detection and quantiﬁcation of
nePTM and their targets is essential for diagnosis and intervention
in ageing and diseases.Quantiﬁcation: why is it important?
Understanding the biochemistry and metabolism of modiﬁed
proteins has gained increased attention in the last two decades,
imposing a demand for their accurate detection and quantiﬁcation.
Since PTM are regular events which enable native proteins to
perform speciﬁc normal and pathological physiological tasks, their
determination contributes to recognition of a connection between
speciﬁc protein structure and speciﬁc biological role. Analysis of
nePTM covers two distinct features: (i) determination of the
modiﬁcation itself (i.e. chemical group or small entity), such as
number of carbonyl groups, disulﬁde bonds, etc. and their speciﬁc
location in the protein sequence and (ii) determination of the
quantity of the speciﬁcally-modiﬁed protein, such as AGE-albumin
or hemoglobin, in relation to the non-modiﬁed form and/or
between two distinct conditions, e.g. healthy and diseased.
Sometimes, these two aspects cannot be clearly separated.
As in the case with all other measurements, quantiﬁcation of
nePTM must follow the route already established for other ana-
lytes. The pattern may be summarized as follows: Development of suitable methods.
 Analytical characterization and validation of each method.
 Deﬁnition of standard preparations.
 Evaluation of the chosen standard(s) in different methods and
modes of utilization.
 Deﬁnition of control samples.
 Evaluation of methods and their standardization on a large
number of samples, obtained from appropriate reference
populations: healthy young, old, male, female, lean, obese,
meat-eaters, vegetarians, sedentary, involved in recreation,
non-smokers, smokers – the choice of the reference population
depends on the analyte to be determined. Evaluation of the method/standardization on samples obtained
from patients with certain disease(s). Deﬁnition of a potential reference material (RM) from a library
of standards tested. Inter-laboratory testing of unknown samples (ring trial), with
participation of many laboratories. Data analysis.
 Consensus agreement.
 Deﬁnition of RM and reference method (maybe more than
one).
 Assignment of RM production to a metrology institution.
 Periodical inter-laboratory testing, also known as proﬁciency
testing.
The pattern described above will lead to harmonization in
measurement procedures and traceability of the result value to
reliable standard(s), fulﬁlling the general purpose of standardiza-
tion in laboratory measurement, which is to achieve comparability
of results obtained in different laboratories, at different times [34].
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zation procedure are RMs and reference methods. The concept of
metrological traceability, introduced as the principle standardiza-
tion achievement, ensures that the test result is traceable to the
appropriate RM [35]. The RM is a well-deﬁned material, with the
exact value, used to standardize the measurement assay. In con-
trast to the so-called control preparations, which are widely used
in laboratories in every-day work and whose values are assigned
consensus values (obtained after statistical evaluation of great
number of determinations in many laboratories) the RM has a
“true” value. A certain preparation becomes an RM after consensus
agreement of the proﬁciency testing network of laboratories and it
should be applicable for standardization of different methods.
Production of an RM is assigned to a respectable metrology
institution such as the National Institute of Standards and Tech-
nology (NIST), World Health Organization (WHO) or National
Institute for Biological Standards and Control (NIBSC) [36]. The RM
is distributed to ﬁnal users together with a certiﬁcate declaring its
characteristics (including limitations such as cross-reactivity or
inapplicability for certain methods) when it becomes a certiﬁed
RM (CRM). Documents published by the International Organiza-
tion for Standardization (ISO) outline theory and guidelines for the
application of RMs. One of them is ISO Standard 17,511:2003:
Guidelines for calibrator traceability.
International agencies of high reputation or an interconnected
network of laboratories decide which methods are suitable to
become reference ones. Each method is characterized by analytical
parameters: accuracy, sensitivity, precision, repeatability, repro-
ducibility, measurement interval, analytical interference, possible
cross-reactivity with homologous analytes present in the sample.
Analytical parameters can be deﬁned and/or explained as
follows: The measured value of an analyte should be the closest possible
to the accepted reference value (accuracy). The method should measure as low quantities of an analyte as
possible (sensitivity), in order to achieve early detection of
changes, when intervention measures have a greater chance of
success. A method should be precise and the obtained values for mul-
tiple probes scattered as little as possible around the target
value. It is worth noting that measuring precisely is not
necessarily measuring accurately (true value). The analyte in a single sample, assayed in several tests over a
period of time (several days, weeks or months if stored
appropriately), should be measured with the smallest possible
variation in the result (repeatability). The smallest possible variation in the results should be
obtained by measuring a single sample, by the same method,
with identical assay components in different laboratories, on
different equipment, by different operators (reproducibility). The measurement interval should cover the entire range of
normal values plus values below and above, up to several times
the reference limit. Each method, however, has its limitations.
Above (and sometimes below) a certain concentration or
activity, measured values deviate from the initial relation
between the variable and the response. Thus, for each method,
a range of application must be declared. Analytical interference is the effect caused by the inﬂuence of a
sample component which does not itself produce a response in
the measuring reaction, but causes an increase or decrease of
the actual result (e.g. absorbs in the same range of the spec-
trum as the reaction product). As protein families exhibit some degree of structural homology,
it is important to know the cross-reactivity of the reagents with
similar analytes, especially if they cannot be removed beforethe analysis. Thus, the reference method should be deﬁned in
terms of cross-reactivity and recognition of homologous
species.
Although not a parameter of the analytical method, but still
very important for analytical performance of a test, is the matrix
effect. It is an intrinsic property of a sample, which does not
augment or depress the measuring signal, but inﬂuences the
measuring process and the ﬁnal value (e.g. sample viscosity) sys-
tematically and more in a technical manner.Quantiﬁcation: why is it hard?
Methods for quantiﬁcation of simple and small analytes are
relatively easily and reliably standardized, such as those for
determination of glucose, cholesterol, ions. It is a much harder task
to standardize methods for quantiﬁcation of complex and large
analytes, such as proteins, in physiological ﬂuids or cell/tissue
samples [37]. There are many obstacles to the standardization and
quality control pathways and some speciﬁc ones for PTMs are
discussed here.
If the analytical aim is to measure the speciﬁc protein in its
native form, the choice of methods is very limited. Applicability of
the method in every-day routine measurement imposes a further
limitation. So-called “high-throughput” techniques that can han-
dle many samples in a relatively short period of time are
demanded in clinical practice. Finally, the concept of “cost-effec-
tiveness” also has to be taken into account. Therefore, considering
all analytical, clinical and practical aspects of PTM quantiﬁcation,
the demands can be summarized as follows: Reliable identiﬁcation of nePTM which are directly correlated
to the speciﬁc modifying reaction or reactive species which
causes it. High speciﬁcity of intra-molecular nePTM recognition (as little
as possible cross-recognition with similar nePTM within the
same protein). High speciﬁcity of inter-molecular nePTM recognition (as little
as possible cross-recognition of the same nePTM in different
proteins). High sensitivity of nePTM recognition (detection of minor
modiﬁcation, just a single one if possible). “Acceptable justiﬁcation” concerning determination of speciﬁc
nePTM in relation to the speciﬁc (patho)physiological
disturbance. “High-throughput” method and the equipment to support it.
In the following paragraphs, problems in satisfying these
demands are discussed.Immunochemical assays for quantiﬁcation of nePTM proteins
Speciﬁc proteins are most often measured by immunochemical
methods, as immunoassays have been shown to possess the most
optimal combination of the requested characteristics listed above.
In contrast to methods for determination of simple analytes, which
are based on simple stoichiometric relation between reactants,
immunochemical methods are based on conformational recogni-
tion and afﬁnity-binding [38].
Protein standards and physiological samples do not necessarily
contain the same molecules. Standards represent only “the most
frequent” combination. Many proteins exist in several isoforms,
which may be present in diverse ratios, contributing to both inter-
individual and intra-individual differences [39]. Follow-up studies
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among proteins, both in terms of quantity and isoform frequency,
may be as much as 30% in a relatively short period of time (several
months and even several weeks) [40]. The situation becomes more
complicated due to natural ageing or in the case of disease,
introducing new molecular forms.
Numerous modiﬁed derivatives of proteins are produced by the
activity of many agents. Several modiﬁcations may occur within a
single protein, some of which affect only one site and others
multiple sites, forming an array of products. Many proteins give
rise to an enormous number of variants. Two major problems in
the determination of proteins are (i) how to recognize reliably the
speciﬁc molecular protein form without interference by other,
similar forms and (ii) how to recognize and measure a speciﬁc
modiﬁcation (or product) of a single protein without detecting the
same modiﬁcation present on another protein. Up to now, results
have been only partially satisfactory.
The nePTM products are often unstable and degrade or change
further immediately after sampling [41]. In order to be measured,
these derivatives need to be relatively stable. When we consider
relative stability, this means that speciﬁc protein forms are stable
for at least a few hours, which is the minimum time needed for
sample preparation and assay performance.
Conﬁdence concerning standardization is not equal for all
methods and may depend on technique. Even assay buffer content
has been demonstrated to inﬂuence the measurement [42]. The
presence of detergents may be necessary for complete solubiliza-
tion of the standard or RM, but it may interfere with the deter-
mination in some methods.
Sensitivities of different methods vary several-fold. Physiolo-
gical samples may be assayed directly in some methods but in
others they must be diluted before being used (very often). Any
manipulation with a sample can cause change in the nePTM, giv-
ing an inaccurate result. A standard or RM should preferably have
a concentration/activity in the middle of the detection range for a
speciﬁc method. As analytical ranges of different methods also
vary several-fold, an alternative solution for standardization and
quality control is production of a set of standards or RMs, with
different concentrations or activities.
Assay response should be directly proportional to the amount
of nePTM, but that is the case only when all modiﬁcations are
available (i.e. exposed at the protein surface). If they are not, their
“visibility” by the reagent depends on the conformational avail-
ability. In the previous chapter on folding and binding properties
of proteins, we described variables that inﬂuence the conforma-
tion of a protein. Exposure of the speciﬁc PTM to be detected and
measured depends on many factors, environmental ones being
among the most important.
In the ﬁeld of nePTM proteins there are no (C)RMs except for
glycated hemoglobin (HbA1c), and there are no internationally
accepted reference method(s). The absence of international stan-
dardization has initiated national standardization organizations to
establish national reference methods. A step further in standar-
dization of HbA1c quantiﬁcation was made by the International
Federation of Clinical Chemistry and Laboratory Medicine (IFCC)
Work Group which announced that reference measurement pro-
cedures for HbA1c are HPLC–MS or HPLC–CE [43].
The general lack of RMs and/or standards has resulted in
research based on nePTM preparations produced mostly “in
house”, together with a range of experimental data for the same
subject, some of which is in disagreement. An additional con-
sequence of non-existent RMs is variation in analytical character-
istics and performance of commercial assays for quantiﬁcation of
PTMs, as manufacturers of in vitro diagnostic tests (IVD tests)
apply their own standardization procedures using their own
standards.Spectrometric methods for quantiﬁcation of nePTM proteins
Besides immunoassays, other methods are used for determina-
tion of nePTM, but not many are suitable for nePTM quantiﬁcation.
Spectrophotometric methods are employed for the measurement of
one particular nePTM on all proteins in a sample. Other spectro-
metric methods, such as Raman and nuclear magnetic resonance
(NMR) spectroscopy can identify speciﬁc nePTM and their positions
within the molecule, but they need an isolated protein. Mass
spectrometry (MS) is assumed to be the most precise method for
detection and location of a speciﬁc modiﬁcation. Since oxidative
protein modiﬁcations are the most common nePTM related to
ageing and disease, standardization of their quantiﬁcation by MS
will be discussed in more detail.
MS is an important tool in the discovery and characterization of
nePTM proteins. It allows for accurate mapping of modiﬁcation
sites in the primary structure of a protein. It can also be used for
quantifying the abundance of the peptide carrying the modiﬁed
residue and to estimate either its modiﬁcation level in relation to
the unmodiﬁed peptides or between two or more different bio-
logical conditions. Thus, MS appears to be an ultimate tool that
should be used for characterizing protein modiﬁcation standards.
The unique feature of MS is that it can be used to analyze any
protein modiﬁcation without a priori assumptions about the type
of modiﬁcation. Based on the mass difference between the gen-
ome deduced protein sequence and peptide masses observed
experimentally it is possible to identify any protein modiﬁcation
(reviewed in [44]). For example, oxidation of a Met residue
(131 Da) increases its mass to 147 Da by the addition of single
oxygen atom (16 Da). Through observation of the discrete mass
difference of the intact protein or peptide it is possible to assign
the respective modiﬁcation. Additionally, mass spectrometry
based sequencing allows for site-speciﬁc assignment of modiﬁca-
tions at the resolution of individual amino-acids [45–47].
Although modern mass spectrometry instruments have
exceptional sensitivity and can detect peptides at sub-femtomole
levels [48], investigation of protein nePTM is still an analytical
challenge (for a review, see [49]). This is mainly because modiﬁed
proteins occur at very low levels in cells. Therefore, modiﬁcation of
a given site is often present in only a small fraction of the protein
molecules of a given type. This phenomenon is also true for oxi-
dized proteins.
Mass spectrometry relies on ionization of the peptides that are
measured. In positive-ion operating mode, ionization of peptides
strongly depends on the presence of basic sites like N-terminal
amine and the side groups of Lys, Arg and His residues. Generation
of some modiﬁcations, e.g. carbonyl products of Arg and Lys (to
give glutamic and 2-amino-adipic semialdehydes) is associated
with loss of guanidine and ammonia groups, typically carrying a
positive charge. This leads to a decreased ionization efﬁciency and
reduces the chance of detecting those peptides using positive-ion
mode MS.
What makes analysis of oxidized proteins exceptionally chal-
lenging, compared to analysis of phosphorylated or acetylated
proteins, for example, is the existence of many types of oxidative
modiﬁcations of proteins. One of the most diverse oxidative
modiﬁcations is carbonylation. Carbonylated residues can occur on
amino-acid side chains, or can reside on the N-terminus of a
cleaved protein; they can also be introduced into proteins by
conjugation with oxidized lipids and carbohydrates. A compre-
hensive list of carbonylated residues can be found in [50]. Apart
from carbonylation many other oxidative modiﬁcations can be
introduced into different amino-acids. These may co-exist in oxi-
dized proteins together with carbonylated residues [50].
The technical challenges related to the identiﬁcation of protein
nePTM have led scientists to develop speciﬁc strategies that allow
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modiﬁcation. This is typically achieved via speciﬁc enrichment
and/or chemical derivatization methods that target a certain class
of modiﬁcations. This creates a “handle” by which modiﬁed pep-
tides/proteins can be pooled out from the bulk of non-modiﬁed
ones. Examples of analytical strategies aimed at nePMT enrich-
ment are use of TiO2 for phosphorylated proteins [49,51], use of
biotin hydrazide for carbonylated proteins [50] or use of iodo-TMT
to label and enrich proteins carrying oxidized Cys residues [52].
NePTM can also be analyzed by MS in “bottom up” experiments
that rely on sample proteolysis prior to mass spectrometric
detection or in “top-down” experiments that analyze intact pro-
teins. The top down experiments provide more information about
individual proteins, including full characterization of each protein
form present and its modiﬁcations [53]. However, top-down pro-
teomics is a relatively immature ﬁeld compared to bottom-up
proteomics, and still suffers from serious limitations [54].
Comprehensive interpretation of MS data obtained from
nePTM focused experiments is an additional analytical challenge.
The complexity of the data and limitations of the existing tools for
bioinformatics very often lead to misinterpretation of the results.
For example, modiﬁcation of Lys and Arg residues frequently
makes them inaccessible for trypsin proteolysis leading to a large
number of missed cleavages. The resulting peptides require large
numbers of missed cleavages to be included in data analysis
algorithms increasing the chance of false positive identiﬁcations.
Another difﬁculty comes from the many different modiﬁcations
that need to be included. Searching algorithms (e.g. Mascot) often
cannot search with an unlimited number of modiﬁcations,
necessitating several searches of the same data. This increases data
processing time and the risk of false positive identiﬁcations. New
types of modiﬁcations can only be found if manual data analysis is
carried out, but this approach is labor intensive, time consuming
and cannot be used effectively with complex protein mixtures.
Identiﬁcation of oxidized peptides with a search algorithm poses
several other technical problems. For detailed discussion of
bioinformatics challenges in identiﬁcation of carbonylated resi-
dues please see the review [50].
In spite of the difﬁculties in identifying carbonylation sites, the
combination of labeling and enrichment methods described above
has led to the identiﬁcation of several hundred carbonylation sites
in speciﬁc proteins [50].
Modern protein mass spectrometry techniques are used both to
detect nePTM and to quantify their amount. This can be done
either as relative measurement deﬁning the difference between
two conditions, e.g. diseased versus control sample or as an
absolute measurement. Combined measurements of modiﬁed and
unmodiﬁed forms of a particular peptide allow the percentage site
occupancy to be deﬁned, i.e. the number of modiﬁed molecules in
relation to the number of unmodiﬁed molecules [52].
The most commonly used quantitative strategy in proteomics is
relative quantitation. This can be achieved using several different
techniques, for example the stable isotope labeling by amino acids
in cell culture (SILAC) approach [55,56], various chemical labeling
procedures, e.g. trypsin-catalyzed 18O labeling [57] or dimethyl
labeling [58,59] or by isobaric labeling, i.e. Isobaric tag for relative
and absolute quantitation (iTRAQ) and Tandem mass tag (TMT).
Absolute quantitation of peptides and proteins is used to deter-
mine exact amounts of the analyzed samples. This is often
achieved by spiking known amounts of heavy-labeled standards
into the sample prior to LC–MSMS analysis and subsequently
comparing the intensities of such standards and the analyte.
Examples of this approach are AQUA [60] and QconCAT [61], which
utilize isotope labeled peptides.
Multiple reactions monitoring (MRM) or single or selected
reaction monitoring (SRM) is a targeted MS based quantitativeapproach. This technique allows measurement of the quantity of
speciﬁc peptides of interest, selected according to their m/z and
fragment ions generated upon MS–MS fragmentation. The result-
ing fragment ions conﬁrm the identity of the precursor and their
intensity is proportional to its abundance. This technique is often
described as “large scale Western blotting” because it allows for
simultaneous quantiﬁcation of up to 100 proteins in one LC MS-
SRM experiment [62]. Use of synthetic isotope labeled peptide
equivalents as internal standards enables relative or absolute
quantitation in SRM experiments. Unfortunately, most oxidative
modiﬁcations are not available through commercial sources of
synthetic peptides. Nevertheless, SRM has the potential to be a
powerful technique for monitoring oxidative modiﬁcations [63].
Comprehensive reviews of different MS based quantiﬁcation
methods can be seen in [64–66].
It is very difﬁcult to obtain inter-laboratory standardization in
the analysis of modiﬁed proteins. This is due to the existence of a
wide variety of instrumental and experimental setups. Over recent
years scientists have become aware of this drawback and now
acknowledge the necessity of standardization and uniﬁcation.
International initiatives have been undertaken during the last few
years. The most prominent is The Human Proteome Organization
(HUPO) Proteomics Standard Initiative (PSI). Its major focus is
standardization of large scale proteomics experiments to facilitate
data validation, accessibility and experimental transparency [67].
As an example of such work it has become a quality standard to
use phosphoRS or similar algorithms to evaluate the probabilities
associated with the precise localization of phosphorylation sites in
peptide sequences [68].
In summary, the range of mass spectrometry based tools for
characterization of protein nePTM is broad. All of these tools have
strong points and limitations (reviewed in [65,69–71]). To take full
advantage of MS technology the experimental aims and the
instrumentation at hand should be carefully considered.Commercial and “in house” made non-enzymatically modiﬁed
proteins
Nowadays it is possible to synthesize peptides with speciﬁc
PTM commercially. This approach is widely used in the ﬁeld of
phosphoproteomics, but other modiﬁcations can also be synthe-
sized. Unfortunately, this does not work so well with protein
oxidation for many reasons, e.g. stability and cross reactivity of the
products. In the case of carbonyls some pseudo-aldehydes can be
used [72].
For the purpose of this article, commercially available modiﬁed
proteins were sought. Several producers of PTM proteins and also
a number of products were found. We use the terms “product” or
“preparation” instead of “standard”, as these items (except HbA1c
from one producer) have not been ofﬁcially recognized as stan-
dards or RMs. Some commercially available modiﬁed proteins are
listed in Table 1. As can be seen, bovine serum albumin (BSA) is the
major substrate used to produce PTM protein. Also, four different
PTM albumin products can be found on the market: nitrated,
glycated, carboxylmethyl-lysine and carbonylated. Thus, according
to the manufacturers’ catalogs, the available PTM proteins are
produced most likely under a standardized regime and deﬁned as
stable preparations with declared characteristics.
Again, for the purpose of this article, we screened the scientiﬁc
literature (approximately 150 papers published between 2000 and
2014), looking for data on the nePTM proteins employed as stan-
dards and discovered that most researchers do not use commercial
modiﬁed proteins, but “in house” made preparations. Commercial
nePTM proteins were quoted in less than 5% of the reports. Ana-
lysis of the frequency of appearance of “in house” made
Table 1
Commercially available modiﬁed proteins.
Modiﬁed protein Producers
Glycated human serum albumin Sigma Aldrich, Exocell Inc.
Glycated human hemoglobin Sigma Aldrich (Fluka), Exocell Inc.
Nitrated bovine serum albumin Sigma Aldrich, Cell Biolabs Inc., Gentaur
Molecular Products, Academy Bio-medical
Co.
Glycated bovine serum albumin Sigma Aldrich, BioVision Inc.
Carboxylmethyl-lysine bovine
serum albumin
Cell Biolabs Inc., Academy Bio-medical Co.
Carbonylated bovine serum
albumin
Cell Biolabs Inc.
Nitrated ovalbumin Gentaur Molecular Products
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Modiﬁcations of ovalbumin, apolipoproteins, collagen, immu-
noglobulins and β-amyloid were reported in several papers each,
while there were sporadic cases when other proteins were mod-
iﬁed to serve as standards. A list of “in house” prepared nePTM
proteins to be used as standards is given in Table 2.
A further literature search led us to conclude that the majority
of researchers investigate protein (glyco, lipo)oxidation. Therefore,
we turned back to the datasheets which accompany commercial
oxidized proteins aiming to investigate the characteristics and
application opportunities of each preparation. The initial idea was
to compare them. Unfortunately, that could not be done, as the
available data accompanying the products differed. Here is a col-
lection of information announced by different producers:
(i) number of modiﬁed residues per molecule of protein, (ii)
identity of the reactive species used for modiﬁcation, (iii) the
change in ﬂuorescence of the modiﬁed molecule compared to the
native one, (iv) the method in which the product can be used.
Introduction of the standardization concept in “standard” pro-
duction and characterization will certainly increase the applicative
potential of commercial nePTM proteins.
Obviously, there is a need for reliable standards, produced and
tested under strict conditions and precisely characterized in
respect to the type of PTM, the quantity and, if possible, the
position within the relevant protein molecule. As previously
mentioned, there is only one CRM in the ﬁeld of nePTM proteins
and that is glycated human hemoglobin IRMM IFCC466. In their
product datasheets manufacturers of IVD tests for quantiﬁcation of
HbA1c declare that they use this CRM to assign values for their
calibrators which are prepared from pooled human erythrocytes.
Manufacturers of immunoassays for quantiﬁcation of HbA1c have
even adopted identical test procedures in respect to concentra-
tions and volumes of the reactants, times of incubation and
wavelength to record the absorbance. A laboratory investigation
(in INEP) on HbA1c immunoassay kits sold by three producers
(Human, Germany; Elitech, France and Point Scientiﬁc, USA)
demonstrated complete cross-reactivity of the calibrators in threeTable 2
“In house” made nePTM proteins.
Modiﬁed protein Frequency of
application (%)
Serum albumin (BSAþHSAþrodent SA) 50þ16þ7¼73
Ovalbumin 3
Apolipoproteins 4
Collagen 5
Immunoglobulins 3
Beta-amyloid 5
Others (insulin, papain, myoglobin, RNAse, lactoglo-
bulin, hemoglobin, crystalline, various enzymes,
membrane proteins)
7assays and overlapping of standard curves (data not shown). In
other words, the calibrators from one assay kit can be used for
calibration of the assay produced by another manufacturer.Strategy to implement standardization and quality control in
quantiﬁcation of protein modiﬁcations
Standardization and quality control are necessary elements in
quantiﬁcation of PTM proteins. Since there are two aspects of PTM
protein quantiﬁcation, each standardization needs to be handled
separately. If the idea is to quantify certain PTM which may be
present on many proteins, a common standard possessing the
particular PTMmay be used. If the idea is to quantify a certain PTM
on a speciﬁc protein, the standard can be that same protein
modiﬁed to express that particular PTM. Alternatively, for the
second purpose, the speciﬁc protein may be isolated and then
measured against a common protein standard which has the
appropriate PTM. In either case, the ﬁrst step is to deﬁne suitable
standard(s).
It is reasonable to choose a standard among already existing
commercial products instead of creating new one(s), as manu-
facturers have probably already solved practical problems con-
cerning continuous production of PTM proteins, their stabilization
and storage. The next step is to network research laboratories and
IVD test manufacturers to participate in inter-laboratory testing in
order to determine the suitability of standards for different
methods, sample types and purposes. Inter-laboratory (ring)
testing will display the strengths and weaknesses of each method.
The most difﬁcult analytical task dependent on the quality of
standardization is detection and accurate quantiﬁcation of minor
proteins in complex (physiological) specimens. Since one speciﬁc
nePTM protein is most often a minor fraction in the entire popu-
lation of that protein, the detection range of the nePTM molecule
is several fold lower than for the entire protein. As no ofﬁcial
standardization in the ﬁeld of PTM proteins exists except for
HbA1c, it is reasonable to start with standardization and quality
control in quantiﬁcation of speciﬁc nePTM present on all (or many)
proteins in a chosen sample, as an easier task.
Once the ﬁrst inter-laboratory testing is completed and data
analyzed, the ﬁnal result will most probably point to signiﬁcant
differences between methods and laboratories. According to the
experience from some ring trials, quite often no ﬁrm conclusions
could be drawn regarding the optimal method, as participants
using same method did not obtain comparable results. The most
experienced laboratories submitted the most accurate results.
Thus, successful protein quantiﬁcation requires a combination of
method, equipment and experienced operators. Further adjust-
ments in assay procedures and subsequent inter-laboratory trials
will lead to more encouraging results and, hopefully, to decisions
on potential standard(s), RM(s) and reference method(s).
A multi-center study was conducted in six laboratories across
Europe to validate the measurement of protein carbonyls (PCO)
[73]. ELISA and Western immunoblotting methods were employed
to detect differences in the amount of PCO in protein samples
exposed to UV irradiation for different time intervals. The results
demonstrated that all laboratories measured increased PCO con-
tent in the sample after 5 min of UV irradiation compared to the
native sample. However, half of the laboratories detected less PCO
after protein irradiation for 15 min than for 5 min. It was sug-
gested that the reason for such diversity may be found in errors in
calculating the amount of PCO, due to differences in method
standardization in each laboratory and, to some extent, in proce-
dural differences (i.e. proteolytic cleavage of oxidized proteins).
The authors concluded that highly oxidized proteins were not
effectively measured by the techniques tested in the study.
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methods, some consensus decisions have to be made. The most
important concern the assessment of measurement inaccuracy
and uncertainty. If the test is standardized to have very high
sensitivity, it may record false negative results. If the test is stan-
dardized to have relatively low speciﬁcity, it may give false posi-
tive results.
Measurement uncertainty is a variable characteristic for a
laboratory performing tests. It provides quantitative estimation of
the level of conﬁdence that the particular laboratory is measuring
precisely. Measurement uncertainty (MU) is not a component of
assay standardization, but it is an integral part of quality control.
The implementation of MU is described in ISO Standard
15,189:1995: Guide to the expression of uncertainty in measure-
ment. This was written primarily for laboratories performing
classical physico-chemical measurements. Approaches to imple-
ment MU standards in the measurement of large physiological
molecules, such as proteins, are still being developed.
Following consensus decisions and ofﬁcial recognition of
standards and/or RMs, together with acceptable and/or reference
methods, research and clinical laboratories, as well as IVD manu-
facturers, are obliged to apply ofﬁcial guidelines in standardization
and quality control in nePTM protein quantiﬁcation. Additionally,
implementation of standardization and quality control in test
manufacture will lead to uniﬁcation in analytical characteristics
and performance of commercial IVD assays.
Standardization and quality control are instruments to achieve
comparability of nePTM protein quantiﬁcation results over time
and space, enabling deﬁnition of decision-making criteria that can
be used in health assessment in relation to ageing and diseases.
To conclude, in order to standardize the quantiﬁcation of cer-
tain nePTM proteins, we propose the following: Creation of a formal group responsible for standardization
(suggestion: from appropriate scientiﬁc societies, IVD produ-
cers, possibly from stakeholders responsible for health). The choice of one commercial nePTM protein to be treated as
the standard (suggestion: the nePTM most often studied, i.e.
carbonylation; the protein most often determined, i.e. albumin;
from a manufacturer with stable production of the speciﬁc
material over several years). Networking as many laboratories as possible to participate in a
standardization trial (suggestion: open call via scientiﬁc
societies; including producers of commercial IVD assays;
optional, to see whether the producer of the chosen nePTM
protein is interested in participation, which may lower the cost
of the trial). Distribution of the material together with instructions and
form (suggestion: the form should contain questions both on
technical aspects of method/instrument and the experience of
the laboratory; perhaps “on-line” form). Data collection and analysis.
 Decision on outcomes of standardization: applicability of the
chosen nePTM protein as the standard for the methods used,
intra- and inter-assay variations, determination of standard
stability, selection of most reliable laboratory(s). Decision on participants for quality control trial (suggestion:
deﬁnition of inclusion criteria based on the results of the
standardization trial) Distribution of the quality control sample(s) with instructions
and form (suggestion: 1–3 samples, could be either commercial
or made in a reliable laboratory and tested for stability). Data collection and analysis.
 Decision on outcomes of the quality control testing: applic-
ability of the quality control samples for the methods used,
conﬁrmation of the most reliable laboratories. Final decisions: (i) is the commercial nePTM protein used sui-
table to be termed “standard” and (ii) are the quality control
samples used suitable to be ofﬁcially termed “quality control
(or proﬁciency testing) samples”? Publication of results, dissemination of conclusions, organiza-
tion of proﬁciency testing scheme, implementation of stan-
dardization in production of commercial IVD assays.Conﬂicts of interest
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